Table 6 Application of PDX-IM model in preclinical or clinical studies of several common tumors
Tumor type | Drug name | Implantation site | Therapeutic target | Application | References |
|---|---|---|---|---|---|
Lung cancer | Gefitinib | Subcutaneous | EGFR | Drug resistance mechanism study | [142] |
ASK120067 | Subcutaneous | EGFR | Novel drug validation | [143] | |
GSK2849330 | Subcutaneous | HER3 | Drug combination validation | [144] | |
HER3-DXd | Subcutaneous | HER3 | Novel drug preclinical validation | [145] | |
Gefitinib | Subcutaneous | EGFR | Drug resistance mechanism study | [146] | |
Breast cancer | AZD4547, BLU9931 | Mammary fat pad | FGFR1, FGFR2, FGFR4 | Therapeutic target identification | [147] |
BYL-719, selumetinib | – | PI3K, MEK | Drug combination validation | [148] | |
BAY80-6946, PF-04691502, AZD2014 | – | PI3K p110α subunit, mTOR and PI3K, mTORC1 and mTORC2 | Therapeutic target identification | [149] | |
MLN0128, trastuzumab | Mammary fat pad | dual mTOR complex, HER2 | Drug combination validation | [150] | |
U3-1402 | Subcutaneous/mammary fat pad | HER3 | Novel drug validation | [151] | |
Pan-HER | Mammary fat pad | Pan-HER antibody mixture against EGFR, HER2, and HER3 | Drug combination validation | [152] | |
Docetaxel, 5-fluorouracil, Trastuzumab | Mammary fat pad | – | Novel drug validation | [153] | |
Docetaxel, doxorubicin, trastuzumab + Lap | Mammary fat pad | – | Novel drug validation | [68] | |
Pancreatic ductal adenocarcinoma | Trametinib | Subcutaneous | MEK | Drug combination validation | [154] |
Gemcitabine | Heterotopic | – | Drug resistance mechanism study | [155] | |
Ovarian cancer | Pertuzumab/trastuzumab | Intraperitoneal (IP) injection | HER2 | Drug combination validation | [156] |
Cisplatin | Heterotopic | – | Drug resistance mechanism study | [157] | |
Pancreatic tumor | Compound 36 l | – | KRAS‒PDEδ | Novel drug preclinical validation | [158] |
Palbociclib, Trametinib | Subcutaneous | CDK4/6, MEK | Drug combination validation | [159] | |
Gastric cancer | Avapritinib | – | Mutated KIT | Novel drug preclinical validation | [160] |
Lenvatinib | Subcutaneous | Multitargeted tyrosine kinase inhibitor | Novel drug preclinical validation | [161] | |
Regorafenib | Subcutaneous | VEGFR, MVD | Novel drug preclinical validation | [162] | |
Colorectal cancer | Cetuximab, LSN3074753 | – | EGFR, RAF | Drug combination validation | [163] |
Cetuximab, Panitumumab | Subcutaneous | HER2 | Therapeutic target identification | [135] | |
WT KRAS | Subcutaneous | IGF2 | Therapeutic target identification | [164] | |
Oxaliplatin | Heterotopic | – | Drug resistance mechanism study | [165] |